Composition comprising biodegradable hydrating ceramics for controlled drug delivery

• US 9,034,359 B2
• Filed: 02/27/2012
• Issued: 05/19/2015
• Est. Priority Date: 10/22/2003
• Status: Active Grant

• Current Assignee: LIDDS AB
• Original Assignee: LIDDS AB
• Inventors: Lennerns, Hans, Lennerns, Bo, Hugosson, Jonas, Axn, Niklas
• Primary Examiner(s): Wax, Robert A
• Assistant Examiner(s): AL-AWADI, DANAH J
• Application Number:
  US13/405,887
• Publication Number:
  US 20120219601A1
• Time in Patent Office: 1,177 Days
• Field of Search: None
• US Class Current: 424/423
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/1611 Inorganic compounds
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The present invention relates to a drug carrier composition comprising i) one or more biodegradable hydrating ceramics ii) one or more expandable agents, and iii) sorbed aqueous medium which in solid form has a ruptured structure. The function of the expandable agent is to create a ruptured structure in the solidified composition, either a foam-like structure or a disintegrated structure where it is split into a large number of parts, particles, units, granules or pieces, so as to obtain an enlarged apparent surface area that is exposed to degradation or erosion upon administration. Suitable substances to obtain this surface enlarging effect are gas-forming agents or swelling agents, gelling agents or disintegrants, here referred to as expandable agents. The expandable agents may be bioresorbable or non-bioresorbable.

Claims

1. A pharmaceutical composition which, when solidified, has a ruptured structure, said composition consisting of

i) one or more biodegradable hydrating ceramics;

ii) one or more agents in an amount sufficient to contribute to the creation of the ruptured structure, wherein said one or more agents are

a) one or more gas-forming agents creating a foam-like structure, wherein the foam-like structure has openings, wherein at least 50% or more of the openings have a maximum width of at least about 0.1 mm;

or

b) one or more disintegrants capable of disintegrating the solidified material into two or more parts;

iii) one or more therapeutically and/or diagnostically active substances; and

iv) sorbed aqueous medium.

2. The pharmaceutical composition according to claim 1, wherein the one or more therapeutically and/or diagnostically active substances is an androgen or a derivative thereof, an anti-androgen or a derivative thereof, an oestrogen or a derivative thereof, an anti-oestrogen or a derivative thereof, a gestagen or a derivative thereof, an anti-gestagen or a derivative thereof, an oligonucleotide, a progestagen or a derivative thereof, a gonadotropin-releasing hormone or an analogue or derivative thereof, a gonadotropin inhibitor or a derivative thereof, an adrenal and/or prostate enzyme inhibitor, a membrane efflux and/or membrane transport protein, an immune system modulator, an angiogenesis inhibitor, or combinations thereof.

3. The pharmaceutical composition according to claim 1, wherein the active substance is flutamide, hydroxy-flutamide, cyproteron, nilutamide or bicalutamide or a mixture thereof.

4. The pharmaceutical composition according to claim 1, wherein the active substance is a combination of an anti-androgen and a gonadotropin-releasing hormone or an analogue thereof.

5. The pharmaceutical composition according to claim 1, wherein the biodegradable hydrating ceramic is selected from the group consisting of:

non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof.

6. The pharmaceutical composition according to claim 1, wherein the agent is a gas-forming agent.

7. The pharmaceutical composition according to claim 1, wherein the solid composition is prepared by curing of said composition, wherein the concentration of the one or more agents in the composition is at least about 0.1% w/w.

8. The pharmaceutical composition according to claim 1, wherein the composition is configured for parenteral use.

9. The pharmaceutical composition according to claim 1, wherein the one or more biodegradable hydrating ceramics have a microporous structure.

10. The pharmaceutical composition according to claim 1, wherein the active substance is controlled released from the composition.

11. A composition in particulate form for use in the preparation of a pharmaceutical composition as defined in claim 1, the composition consisting of:

i) one or more biodegradable hydrating ceramics in powder form;

ii) one or more agents in an amount sufficient to contribute to the creation of a ruptured structure in a solidified composition, wherein said one or more agents are

a) one or more gas-forming agents;

or

b) one or more disintegrants; and

iii) one or more therapeutically and/or diagnostically active substances.

12. A method for treatment of a subject suffering from a prostate disease, comprising administering to the subject a composition as claimed in claim 1, or the solidified form thereof.

13. A method according to claim 12, wherein the prostate disease is prostate cancer or prostate hyperplasia.

14. A method according to claim 12, wherein the active substance is flutamide, hydroxy-flutamide, cyproteron, nilutamide or bicalutamide or a mixture thereof.

15. A method according to claim 12, wherein the active substance is a combination of an anti-androgen and a gonadotropin-releasing hormone or an analogue thereof.

16. A method according to claim 12, wherein the active substance is hydroxyflutamide.

17. A method according to claim 12, wherein the composition is administered to a subject'"'"'s prostate tissue by implantation.

18. The composition according to claim 1 wherein the one or more agents which contribute to the ruptured structure increase the erosion rate of the ceramic.

19. The composition according to claim 1 wherein the one or more therapeutically and/or diagnostically active substances are selected from the group consisting of antibacterial agents, antihistamines and decongestants, anti-inflammatory agents, antiparasitics, antivirals, local anaesthetics, antifungals, amoebicidals or trichomonacidal agents, analgesics, antianxiety agents, anticlotting agents, antiarthritics, antiasthmatics, anticoagulants, anticonvulsants, antidepressants, antidiabetics, antiglaucoma agents, antimalarials, antimicrobials, antineoplastics, antiobesity agents, antipsychotics, antihypertensives, auto-immune disorder agents, anti-impotence agents, anti-Parkinsonism agents, anti-Alzheimers agents, antipyretics, anticholinergics, anti-ulcer agents, anorexics, beta-blockers, beta-2 agonists, alpha receptor antagonists and agonists, blood glucose-lowering agents, bronchodilators, agents with effect on the central nervous system, cardiovascular agents, cognitive enhancers, contraceptives, cholesterol-reducing agents, agents against dyslipidemia, cytostatics, diuretics, germicidals, H-2 blockers, hormonal agents, anti-hormonal agents, hypnotic agents, inotropics, muscle relaxants, muscle contractants, physic energizers, sedatives, sympathomimetics, vasodilators, vasoconstrictors, tranquilizers, electrolyte supplements, vitamins, uricosurics, cardiac glycosides, membrane efflux inhibitors, membrane transport protein inhibitors, expectorants, purgatives, contrast materials, radiopharmaceutical, imaging agents, peptides, enzymes, growth factors, and vaccines.